Quantcast

Latest Protease inhibitors Stories

2015-05-26 20:22:10

- New data from GIFT-I study presented at the Annual Meeting of the Japan Society of Hepatology NORTH CHICAGO, Ill., May 26, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) presented

2015-05-11 08:31:13

Expanded Policy will Increase Access for Darunavir Pediatric Formulations in 128 Resource-Limited Countries RARITAN, N.J., May 11, 2015 /PRNewswire/ -- Johnson & Johnson today

2015-04-25 12:22:45

- RUBY-I evaluates treatment-naïve, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment VIENNA, April 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV)

2015-04-24 08:30:14

As well as results from its Pivotal Phase 3 C-EDGE Programme Evaluating Grazoprevir/Elbasvir Showing High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus

2015-04-15 20:21:58

- AbbVie's investigational, interferon and ribavirin-free treatment in Japan consists of a 12-week, two direct-acting antiviral, fixed-dosed combination of paritaprevir/ritonavir with ombitasvir, dosed

2015-04-08 04:21:19

- 29 abstracts, including sub-analyses of AbbVie's approved treatment of VIEKIRAX® + EXVIERA®, as well as new data from Phase 3b development program and AbbVie's HCV pipeline compounds NORTH

2015-02-23 16:29:39

- In adult patients co-infected with genotype 1 (GT1) hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1), TURQUOISE-I, using VIEKIRA PAK with ribavirin (RBV), demonstrated sustained

2015-02-19 08:34:08

JERUSALEM, February 19, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc.

2015-01-29 16:28:05

Combined Fixed-Dose Tablet of Darunavir and Cobicistat Can Help Reduce Number of Pills in a Combination Antiretroviral Treatment Regimen TITUSVILLE, N.J., Jan.


Word of the Day
begunk
  • To befool; deceive; balk; jilt.
  • An illusion; a trick; a cheat.
The word 'begunk' may come from a nasalised variant of Scots begeck ("to deceive, disappoint"), equivalent to be- +‎ geck.